The first evaluation of consistency of hydrochlorothiazide tablets

On January 11, Shanghai Pharmaceutical announced that Changzhou pharmaceutical, its holding subsidiary, had received the approval document for supplementary application of hydrochlorothiazide tablets (25mg) issued by the State Drug Administration, which passed the consistency evaluation of quality and efficacy of generic drugs Hydrochlorothiazide tablet is an oral diuretic It is used to relieve edema, hypertension, kidney stone, hypercalcemia and other non edema diseases caused by various reasons The original research enterprise is Novartis, which was first listed in the United States in 1959 According to iqvia database, the purchase amount of hydrochlorothiazide tablets in 2017 was 7.76 million yuan, of which Changzhou pharmaceutical sales revenue was 1.77 million yuan According to the pharmaceutical intelligence data, there are 95 domestic approvals for hydrochlorothiazide tablets in China, 74 manufacturers, and 8 enterprises participating in the consistency evaluation of reference filing At present, only Changzhou pharmaceutical has applied for the first review, which is conducive to expanding the market share of the drug, further enhancing the technical advantages and card advantage of the product, and reshaping the market pattern In addition, according to the announcement, Shanghai Pharmaceutical Group, as the leading enterprise in the conformity evaluation of generic drugs, has completed the application for conformity evaluation of 32 solid preparations of product specifications by the end of 2018, and has carried out the conformity evaluation of injections, striving to seize the opportunity Source: Announcement statement of Shanghai Pharmaceutical Enterprise: This article is the integration content, the view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.